Stocks · News reference

Neuropace shares are trading lower after the company announced it received communication from the FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form.

Jul 29, 2026, 12:30 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 11, 2026, 8:08 PMBenzinga Newsdesk
NeuroPace Raises FY2026 Sales Guidance from $99.000M-$101.000M to $99.500M-$101.500M vs $99.913M Est
NeuroPace (NASDAQ:NPCE) raises FY2026 sales outlook from $99.000 million-$101.000 million to $99.500 million-$101.500 million vs $99.913 million estimate.
Read original at benzinga
NPCE
BenzingaAug 11, 2026, 8:07 PMBenzinga Newsdesk
NeuroPace Q2 EPS $(0.18) Beats $(0.20) Estimate, Sales $22.826M Beat $22.654M Estimate
NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 30.77 percent increase over losses of $(0.26) per share from the same
Read original at benzinga
NPCE
BenzingaJul 29, 2026, 12:03 PMAvi Kapoor
Avis Budget Posts Weak Q2 Results, Joins Fiverr International, Costar Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
US stock futures mixed, Dow up 0.1%. Avis Budget Group (CAR) shares down 13.3% after missing earnings & sales estimates. Other stocks also down.
Read original at benzinga
CAR CSGP DCX FEIM FVRR